# KR-402

Source: https://onco.cc/drugs/kr-402/  
OnCo record `kr-402` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KR-402 is an experimental in vivo CAR-T: mRNA in T-cell-targeted lipid nanoparticles from Kernal Biologics, in preclinical development for cancer.

## Summary

KR-402 is an in vivo CAR-T: mRNA in T-cell-targeted lipid nanoparticles from Kernal Biologics. A programme that uses T-cell-targeted lipid nanoparticles carrying mRNA to programme CAR-T cells directly inside the body; the company reports B-cell depletion within a week. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. No registered trial found on ClinicalTrials.gov for KR-402 or KR402 (checked 3 Nov 2026). The CAR target antigen is not stated in any source read. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: KR-402
- Modality: In vivo CAR-T: mRNA in T-cell-targeted lipid nanoparticles
- Mechanism: A programme that uses T-cell-targeted lipid nanoparticles carrying mRNA to programme CAR-T cells directly inside the body; the company reports B-cell depletion within a week.

## Sources

- Kernal Biologics: ycombinator.com: https://www.ycombinator.com/companies/kernal-biologics
- Kernal Biologics: kernalbio.com: https://www.kernalbio.com

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Kernal Biologics](https://onco.cc/companies/kernal-biologics/)

---
JSON: https://onco.cc/api/v1/entities/kr-402.json